The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
 
Laurie Helen Sehn
Honoraria - Abbvie; Acerta Pharma; Amgen; Apobiologix; AstraZeneca; Celgene; Debiopharm Group; Genmab; Gilead Sciences; Incyte; Janssen-Ortho; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; morphosys; Roche/Genentech; Sandoz-Novartis; Seagen; Takeda; Teva; TG Therapeutics; Verastem
Consulting or Advisory Role - Abbvie; Acerta Pharma; Amgen; Amgen; apobiologix; AstraZeneca; Celgene; Debiopharm Group; Genmab; Gilead Sciences; Incyte; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; MorphoSys; Roche/Genentech; Sandoz-Novartis; Seagen; Takeda; Teva; TG therapeutics; TG Therapeutics; Verastem
Research Funding - Roche/Genentech (Inst); Teva (Inst)
 
Kai Hübel
Consulting or Advisory Role - Celgene; EUSA Pharma; Gilead Sciences; Incyte; Roche; SERVIER
 
Stefano Luminari
Consulting or Advisory Role - Celgene; Genmab; Gilead Sciences; Incyte; Regeneron; Roche
Travel, Accommodations, Expenses - Celgene; Janssen
 
Antonio Salar
Consulting or Advisory Role - Celgene; Janssen; Roche
Research Funding - Gilead Sciences
 
Bjorn E. Wahlin
Consulting or Advisory Role - Roche
Research Funding - Gilead Sciences
 
Ajay K. Gopal
Honoraria - Actinium Pharmaceuticals; ADC Therapeutics; Amgen; Cellectar; Epizyme; Gilead Sciences; I-mab; Janssen Oncology; Kite/Gilead; Merck; morphosys; nurix; Pfizer; Seagen; Takeda; TG Therapeutics
Consulting or Advisory Role - Cellectar; Gilead Sciences; I-Mab; Incyte; Janssen Oncology; Kite/Gilead; Millennium; morphosys; nurix; Pfizer; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); I-Mab (Inst); IgM (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst)
 
Christophe Marc Bonnet
Consulting or Advisory Role - Roche
 
Shankara Paneesha
Honoraria - Celgene; Roche
 
Marek Trneny
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; MorphoSys; Novartis; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Incyte; Janssen; MorphoSys; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Gilead Sciences; janssen; Roche; Takeda
 
Hafsat Umar Mashegu
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Christine Francis Lihou
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Research Funding - Incyte (Inst)
 
Di Li
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Christian W. Scholz
Honoraria - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Incyte; Janssen Oncology; Lilly; MSD Oncology; Novartis; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Daiichi Sankyo Europe GmbH; Gilead Sciences; Hexal; Janssen; Merck Serono; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Janssen; Roche